.jpg)
- Current opinion in investigational drugs
-
影響因子：
3.553
-
I S S N：
1472-4472
-
出 版 社：
Thomson Reuters (Scientific) Ltd
-
出 版 地：
London
-
出版國家：
England
-
刊 期：
月刊
-
創(chuàng)刊時(shí)間：
2000
-
語 種：
英文
-
審稿周期：
12周，或約稿
-
中科院分區(qū)：
3
-
投稿命中率：
一般
-
國外數(shù)據(jù)庫收錄：
IM
-
中國收錄文章數(shù)：
1
-
5年影響因子：
3.006
-
研究領(lǐng)域：
抗感染藥物、抗炎劑、抗腫瘤藥、心血管藥物、中樞神經(jīng)系統(tǒng)藥物、臨床試驗(yàn)專題、藥物研究
-
官方鏈接：
http://www.biomedcentral.com/about
-
投稿須知：
http://www.biomedcentral.com/about
期刊介紹：
Current Opinion in Investigational Drugs is a monthly publication covering all therapeutic areas, in recognition of the increasingly multi-disciplinary nature of modern drug discovery and development. With Current Opinion in Investigational Drugs, we aim to help the reader by providing in a systematic manne critical reviews of selected areas of investigational drug research, expert evaluation of selected drugs currently in clinical trials, selection of the most interesting papers and patents, annotated by experts. Six therapeutic categories are covered with each being featured in separate journal issues, and each therapeutic area being covered twice-yearly. The broad therapeutic categories and the specialist topics within each are as follows: Anti-infectives Antifungals and antiparasitics; antibacterials (b-lactams, glycopeptides and other agents); antibacterials (quinolones, macrolides and oxazolidinones); vaccines; antivirals (HIV); antivirals (non-HIV); Anti-inflammatory, Immunologicals and Biologicals Musculoskeletal; respiratory; dermatology; nervous system; transplantation; Cardiovascular and Renal Hypertension and renal failure; stroke and angina; arrhythmia and heart failure; antithrombotics; hemostasis and hematological diseases; atherosclerosis, hypercholesterolemia and heart disease; Endocrine and and Metabolics Diabetes, reproductive endocrinology, hormone disorders, bone metabolism and obesity; Central and Peripheral Nervous System Pain; neuro-urology and neurogastroenterology; neurodegenerative and cognitive disorders; affective/behavioral/personality disorders and substance abuse; neurology and neuroprotection; schizophrenia and psychosis; Oncological Cell signaling modulators; cytotoxic drugs; immunotherapeutic drugs and monoclonal antibodies; protein therapeutics, including growth factors; gene therapy; antisense inhibitors
